Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein.

<h4>Unlabelled</h4>The objectives of this non-randomized, non-blinded, dose-escalating Phase I clinical trial were to assess the safety, reactogenicity and immunogenicity of ICC-1132 formulated with Alhydrogel (aluminum hydroxide) in 51 healthy, malaria-naive adults aged 18 to 45 years....

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Aric L Gregson, Giane Oliveira, Caroline Othoro, J Mauricio Calvo-Calle, George B Thorton, Elizabeth Nardin, Robert Edelman
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2008-02-01
Online Access:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0001556&type=printable